Viiv Healthcare To Announce Data From Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug Regimen Biktarvy At AIDs 2024
Viiv Healthcare To Announce Data From Randomised Clinical Trial For 2-Drug Regimen Dovato Against 3-Drug Regimen Biktarvy At AIDs 2024
維欣醫療公司將在艾滋病2024年會議上公佈2種藥物方案Dovato與3種藥物方案Biktarvy的隨機臨床試驗數據。
-
Findings from the SEIMC-GeSIDA Foundation (FSG) PASO-DOBLE study will include treatment efficacy, safety, and weight gain experienced by participants taking Dovato (dolutegravir/lamivudine) or Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Additional key abstracts from ViiV Healthcare's industry-leading, long-acting pipeline and portfolio include data introducing a third-generation integrase strand transfer inhibitor (INSTI) with potential for ultra long-acting applications; pregnancy data for Apretude (cabotegravir long-acting injectable) for PrEP; and real-world evidence for long-acting treatment regimen Cabenuva (cabotegravir + rilpivirine long-acting)
- SEIMC-GeSIDA基金會(FSG)PASO-DOBLE研究的發現將包括參與者服用Dovato（多烯磷酸酯/拉米夫定）或Biktarvy（比克替格韋/恩替卡韋酯/阿拉芬酰胺）期間的治療效果、安全性和體重增加。
- **** Healthcare領先行業的打破常規產品線和組合中，額外的重要摘要包括引入第三代整合酶鏈轉移抑制劑(INSTI)，具有超長效應用潛力；Apretude(長效注射用卡博替格韋)在PrEP期間的孕婦數據；以及Cabenuva(卡博替格韋+利托猝滅韋長效)長效治療方案的真實世界證據。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。